179 related articles for article (PubMed ID: 21606960)
1. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Blum KA; Ruppert AS; Woyach JA; Jones JA; Andritsos L; Flynn JM; Rovin B; Villalona-Calero M; Ji J; Phelps M; Johnson AJ; Grever MR; Byrd JC
Leukemia; 2011 Sep; 25(9):1444-51. PubMed ID: 21606960
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Ji J; Mould DR; Blum KA; Ruppert AS; Poi M; Zhao Y; Johnson AJ; Byrd JC; Grever MR; Phelps MA
Clin Cancer Res; 2013 Mar; 19(5):1269-80. PubMed ID: 23300276
[TBL] [Abstract][Full Text] [Related]
3. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
Stephens DM; Ruppert AS; Maddocks K; Andritsos L; Baiocchi R; Jones J; Johnson AJ; Smith LL; Zhao Y; Ling Y; Li J; Phelps MA; Grever MR; Byrd JC; Flynn JM
Leuk Res; 2013 Oct; 37(10):1195-9. PubMed ID: 23867058
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
[TBL] [Abstract][Full Text] [Related]
8. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
Cheson BD; Frame JN; Vena D; Quashu N; Sorensen JM
J Clin Oncol; 1998 Jul; 16(7):2313-20. PubMed ID: 9667245
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol in chronic lymphocytic leukemia: a concise review.
Christian BA; Grever MR; Byrd JC; Lin TS
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S179-85. PubMed ID: 19778838
[TBL] [Abstract][Full Text] [Related]
12. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
[TBL] [Abstract][Full Text] [Related]
13. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
Flynn J; Jones J; Johnson AJ; Andritsos L; Maddocks K; Jaglowski S; Hessler J; Grever MR; Im E; Zhou H; Zhu Y; Zhang D; Small K; Bannerji R; Byrd JC
Leukemia; 2015 Jul; 29(7):1524-9. PubMed ID: 25708835
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
[TBL] [Abstract][Full Text] [Related]
15. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
[TBL] [Abstract][Full Text] [Related]
16. Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Investig Drugs; 2016 Jun; 25(6):729-34. PubMed ID: 26998706
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Innocenti F; Stadler WM; Iyer L; Ramírez J; Vokes EE; Ratain MJ
Clin Cancer Res; 2000 Sep; 6(9):3400-5. PubMed ID: 10999721
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
Awan FT; Jones JA; Maddocks K; Poi M; Grever MR; Johnson A; Byrd JC; Andritsos LA
Ann Hematol; 2016 Jun; 95(7):1137-43. PubMed ID: 27118540
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
Stephens DM; Ruppert AS; Blum K; Jones J; Flynn JM; Johnson AJ; Ji J; Phelps MA; Grever MR; Byrd JC
Haematologica; 2012 Mar; 97(3):423-7. PubMed ID: 22271900
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
